Who Owns Xiamen Kingdomway Group Company?

Xiamen Kingdomway Group Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Xiamen Kingdomway Group?

Unraveling the ownership structure of Xiamen Kingdomway Group SWOT Analysis is key to understanding its future. From its humble beginnings in 1997 to its public listing on the Shenzhen Stock Exchange in 2011, the company's ownership has undergone a significant transformation. This deep dive explores the evolution of Kingdomway ownership, from founder stakes to today's major shareholders.

Understanding who owns Kingdomway is vital for any investor or stakeholder. As a publicly traded company, Kingdomway's ownership is dispersed, making it essential to identify the major stakeholders and their influence. This analysis will provide a comprehensive overview of the Kingdomway company, including its history, current market position, and the key players shaping its destiny. We'll explore Kingdomway shareholders and their impact on the company's strategic direction.

Xiamen Kingdomway Group Company was established on November 24, 1997. The company's early focus was on entering the biopharmaceutical sector, with an emphasis on nutritional and pharmaceutical products. This initial strategic direction set the stage for its future growth and development within the industry.

The early years of the company were marked by a commitment to becoming a leading high-tech enterprise. This focus on innovation and quality was evident in its subsequent achievements, such as obtaining GMP (Good Manufacturing Practice) certification for its production facilities. This certification, achieved by 2018, highlights the company's dedication to maintaining high standards.

While precise details regarding the founders' names, initial equity distribution, or shareholding percentages at the company's inception are not readily available in the provided search results, the company's early focus on quality and innovation likely shaped the initial investments and control within the company. The company's early development was characterized by a commitment to becoming a key high-tech enterprise.

Ownership Structure Overview

Information regarding the initial ownership structure of Xiamen Kingdomway Group is limited in the available sources. Details on early backers, angel investors, or family stakes are not readily accessible. The company's early focus was on entering the biopharmaceutical sector. For a broader understanding of the competitive environment, consider exploring the Competitors Landscape of Xiamen Kingdomway Group.

• Specifics on initial shareholding percentages at the company's inception are not available.
• There is no public information detailing early backers, angel investors, or family stakes.
• Details on vesting schedules, buy-sell clauses, or founder exits during the formative years are not provided.
• Information regarding initial ownership disputes is not available in the provided search results.

Xiamen Kingdomway Group SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Xiamen Kingdomway Group's ownership structure is marked by its transition from a private entity to a publicly listed company. This pivotal shift occurred on October 28, 2011, when it was listed on the Shenzhen Stock Exchange under the ticker symbol 002626. The initial public offering (IPO) raised approximately ¥160 million, which translated to around $24 million at the time. This capital injection was instrumental in expanding production capabilities and broadening the company's geographic footprint. As of June 13, 2025, the company's market capitalization has reached approximately $1.53 billion, with 610 million shares outstanding, reflecting substantial growth since its IPO.

The company's ownership structure showcases a diversified base, encompassing institutional investors, individual shareholders, and company insiders. This diversification is a direct result of the company's growth and its increasing appeal to a broader investor base following its public listing. The presence of both institutional and individual investors highlights the company's stability and its potential for long-term growth, which is further detailed in the Growth Strategy of Xiamen Kingdomway Group.

As of September 2024, Xiamen Kingdomway Investment Limited and China Animal Husbandry Industry Co., Ltd. are the major stakeholders. Individual shareholders collectively account for approximately 30% of the ownership. Mr. Wang Jian, as of October 2023, is the largest single individual shareholder, holding 15% of the total shares. The remaining 25% is distributed among various smaller investors and employee stock ownership plans. These shifts in major shareholding reflect the company's growth and its increasing appeal to a broader investor base following its public listing.

Key Takeaways on Kingdomway Ownership

Understanding the ownership structure of Xiamen Kingdomway Group is crucial for investors and stakeholders.

• The company is publicly listed on the Shenzhen Stock Exchange.
• Ownership is diversified, including institutional and individual investors.
• Xiamen Kingdomway Investment Limited and China Animal Husbandry Industry Co., Ltd. are significant shareholders.
• The company's market capitalization is approximately $1.53 billion as of June 13, 2025.

Xiamen Kingdomway Group PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Determining the exact composition of the current board of directors for Xiamen Kingdomway Group is not possible with the information available. The search results do not provide a detailed list of board members, their affiliations, or whether they represent major shareholders or hold independent seats. However, it is known that Bin Jiang serves as both the Legal Representative and General Manager of the company. Further information would be needed to fully understand the board's structure and its influence on the company's strategic decisions.

As a publicly traded entity, Xiamen Kingdomway Group operates under a standard one-share-one-vote system, common among A-share listed companies in China. There is no indication from the provided search results of any special voting rights or dual-class share structures that would grant disproportionate control to specific shareholders. This suggests that voting power is generally aligned with share ownership, and that all shareholders have equal voting rights per share held. For more details on the company's background, you can check out the Brief History of Xiamen Kingdomway Group.

The absence of information on proxy battles, activist investor campaigns, or governance controversies in the search results suggests a period of relative stability in the company's decision-making processes. Without more specific data, it is difficult to assess the level of shareholder activism or the influence of major stakeholders on the company's strategic direction. Further investigation into the company's filings and governance reports would be needed to provide a more detailed picture of the board's composition and voting dynamics.

Understanding Kingdomway Ownership

The ownership structure of Xiamen Kingdomway Group is primarily determined by its shareholders, as it is a publicly traded company. The board of directors, including the Legal Representative and General Manager, oversees the company's operations.

• Shareholders hold voting rights proportional to their share ownership.
• Bin Jiang is the Legal Representative and General Manager.
• No specific details about major shareholders or governance controversies are available in the provided search results.
• The company operates under a standard one-share-one-vote system.

Xiamen Kingdomway Group Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the past few years, Xiamen Kingdomway Group has shown consistent growth. The company's revenue reached RMB 3.24 billion in 2024, reflecting a 4.43% year-on-year increase. Net profits attributable to shareholders rose significantly, increasing by 23.59% to RMB 342 million. The first quarter of 2025 continued this positive trend, with revenue of CNY 827.24 million, an 11.31% increase year-on-year, and a substantial 71.97% rise in net income to CNY 121.74 million.

Regarding the ownership structure, the total shares outstanding for Xiamen Kingdomway Group have remained stable at 610 million from December 2023 through March 2025. There were no substantial share repurchases, as indicated by a 0.00% share buyback ratio during the six months leading up to March 2025. The company has a history of strategic acquisitions, including stakes in Jiangsu Chengxin Pharmaceutical Co., Ltd. Furthermore, the establishment of subsidiaries like Xiamen Kingdomway Biotech Co., Ltd. (2010) and Xiamen Kingdomway Electronic Commerce Co., Ltd. (2014) demonstrates internal expansion and diversification efforts.

The provided information does not include any public statements concerning future ownership changes, succession plans, or potential privatization or public listing of the company. This suggests that the current ownership structure and strategic direction are likely to remain consistent in the immediate future, focusing on organic growth and strategic acquisitions to enhance market position.

Key Financial Data (2024)

Revenue: RMB 3.24 billion. Net Profit: RMB 342 million. Year-on-year revenue growth: 4.43%. Increase in net profit attributable to shareholders: 23.59%.

Recent Share Information

Shares Outstanding: 610 million (Dec 2023 - Mar 2025). Share Buyback Ratio (as of March 2025): 0.00%. This indicates no significant share repurchases.

Strategic Acquisitions

Acquisition of a 57.6% stake in Jiangsu Chengxin Pharmaceutical Co., Ltd. Further investment of 28.41% stake in the same company for CNY 100 million. These acquisitions demonstrate the company's expansion strategy.

Subsidiary Establishments

Xiamen Kingdomway Biotech Co., Ltd. (established in 2010). Xiamen Kingdomway Electronic Commerce Co., Ltd. (established in 2014). These subsidiaries showcase internal growth and diversification.

Xiamen Kingdomway Group Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs